Proceedings of the National Academy of Sciences · 1993 · 220 citations · 36 references
Life SciencesImmunologyImmunopathologyImmunotherapyTransplant ImmunologyCytokine-mediated PathologyT Cell Responses To TumorsCd4 Positive T CellsCd4 T-cell DepletionCd8 Positive T CellsCytokine-mediated RejectionCytokine-mediated T Cell ActivationCytokine-mediated T Cell ResponsesImmune Cell Gene TransferT Cell Cytokine Production
Interleukin (IL)-2, IL-4, IL-7, tumor necrosis factor (TNF), or interferon-gamma (IFN-gamma) has been shown to be able to induce tumor rejection if produced locally by the tumor cells after gene transfer. To analyze whether the cellular rejection mechanisms are different or redundant we have expressed the cytokines in the same tumor cell line (J558L). Cell depletion experiments revealed that all cytokines required CD8+ T cells for complete long-term tumor eradication, although effective but transient host-dependent tumor suppression was also observed in the complete absence of CD8+ T cells. The transient tumor suppression induced by IL-2, IL-4, TNF, or IFN-gamma was also operative in nude and severe combined immunodeficient mice, whereas only tumor suppression induced by IL-7 was dependent on the presence of CD4+ T cells and was not evident in nude mice. The T-cell-independent effector arm of IL-2 and IFN-gamma but not IL-4 and TNF was mediated in part by natural killer cells. The transience of tumor suppression in the absence of T cells reflected loss of cytokine production in the case of TNF, IL-2, and IL-4 but not IFN-gamma. Immunohistologic analysis revealed all cytokine-producing tumors to be heavily infiltrated by macrophages. IL-4 and IL-7 tumors additionally contained eosinophils. The infiltration by T cells did not necessarily reflect their contribution to tumor rejection. Thus, the different cytokines activate heterogeneous transient tumor-suppressive mechanisms but always require CD8+ T cells for complete tumor rejection.
36
T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity
Steven Gillis, Mary M. Ferm, Winny Ou et al. · The Journal of Immunology · 1978 · 3.3K citations · Full text
Holly Cherwinski, J H Schumacher, Kenneth D. Brown et al. · The Journal of Experimental Medicine · 1987 · 1K citations · Full text
Murine interleukin-4 displays potent anti-tumor activity in vivo
Robert I. Tepper, Paul K. Pattengale, Philip Leder · Cell · 1989 · 780 citations
Medicine, Immunology, Oncology +10